News

#The Wall Street Journal: CureVac says COVID-19 vaccine was 48% effective in key study

CureVac says its COVID vaccine was poor match against 29 COVID variants, as global case tally tops 177 million

Table of Contents

“#The Wall Street Journal: CureVac says COVID-19 vaccine was 48% effective in key study”

German company CureVac
CVAC,
+8.92%
released the final results for its once-promising Covid-19 vaccine, finding it provided less protection than the vaccines already authorized for use in the U.S.

The company said Wednesday that its vaccine was 48% effective in providing protection against Covid-19 of any severity, regardless of age, in a large, pivotal study.

Shares in CureVac fell nearly 9% in after-hours trading, with shares trading around $67.27 after closing at $73.48 earlier in the day.

An expanded version of this story is available at WSJ.com

Laura Cooper

If you liked the article, do not forget to share it with your friends. Follow us on Google News too, click on the star and choose us from your favorites.